Hims & Hers Health Q2 2024 GAAP EPS $0.06 Beats $0.03 Estimate, Sales $315.648M Beat $299.942M Estimate
Portfolio Pulse from Benzinga Newsdesk
Hims & Hers Health (NYSE:HIMS) reported Q2 2024 earnings per share (EPS) of $0.06, surpassing the analyst estimate of $0.03. The company also reported sales of $315.648 million, exceeding the estimate of $299.942 million. This represents a significant improvement from the same period last year, with EPS increasing by 300% and sales by 51.82%.
August 05, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hims & Hers Health reported Q2 2024 EPS of $0.06, beating the analyst estimate of $0.03 by 100%. Sales were $315.648 million, exceeding the estimate of $299.942 million. This marks a 300% increase in EPS and a 51.82% increase in sales compared to the same period last year.
The significant beat on both EPS and sales, along with substantial year-over-year growth, is likely to positively impact HIMS stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100